This multi-million dollar research contract will focus on risk assessment and reduction in cardiovascular disease and other disease areas of interest to the customer. Entelos will receive technology license fees and R&D funding for the next three years.
James Karis, president and CEO of Entelos, said: “In this new application, we will be expanding its use to test the effects of ‘virtual products’ on ‘virtual consumers’, representations of unique genetic, biologic, and lifestyle profiles. We can then use our technology to optimize product designs to improve human health.”